Momentum Obesity Trial

What is the Momentum Obesity Trial?

The Momentum Phase 2 Obesity Trial is currently closed for enrollment and is not accepting new participants at this time.

The study was designed to evaluate whether ALT-801 (also called pemvidutide, the proposed INN name for this drug) can safely induce weight loss in people with excess weight or obesity. It also assessed quality of life and improvement in other conditions associated with excess weight and obesity, such as high blood pressure, high cholesterol, and predisposition to diabetes.

Who can join the Momentum Obesity Trial?

Study participants may be able to join the trial if they meet the following requirements*:

* Other study requirements will apply, as will be explained by the study doctor at the study site

What will happen during the study?

Participation in the Momentum study lasts about 13 months. Study participants can expect the following:

Informed Consent

Review & sign the
Informed Consent Form

Screening

Receive study health assessments to confirm if you qualify for the study.

Treatment Period

Receive the study drug or placebo administered subcutaneously once a week for 48 weeks. Throughout the trial, your study team will monitor your health and will provide you with regular counseling on diet and exercise.

Follow-up Period

Receive study health assessments and complete a study follow-up visit one month after completing treatments.

Participation in a clinical study is voluntary. You can ask any questions you have and may leave the study at any time, for any reason.

Visit clinicaltrials.gov to learn more about the Momentum Obesity Trial.